In today’s briefing:
- Pre-IPO Remegen Co Ltd – Some Points Worth the Attention
Pre-IPO Remegen Co Ltd – Some Points Worth the Attention
- RC48’s commercialization performance in China market could be lower than expected. The breakthrough point is whether the deal with Seagen can bring any surprise in the global markets.
- Due to large R&D and selling expenses, Remegen Co Ltd (9995 HK) is facing cash flow pressure, indicating that this IPO in SSE STAR market is very important for the Company.
- Let’s see if RemeGen would in-license some unique late-stage candidates or reach new blockbuster license-out deals that surprise us again, both of which would help turn things around.
Before it’s here, it’s on Smartkarma
